Analyst Reco. Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Real-time Estimate Cboe BZX Other stock markets 16:50:13 03/05/2024 BST			5-day change	1st Jan Change
23.32 ^USD	-0.91%		+0.60%	-16.26%

04-15	Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating	MT
04-12	Pharvaris Files Mixed Shelf	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating	04-15	MT
JMP Securities Raises Pharvaris' Price Target to $49 From $40, Maintains Market Outperform Rating	01-23	MT
Morgan Stanley Raises Price Target on Pharvaris to $35 From $32, Keeps Overweight Rating	12-07	MT
Wedbush Raises Pharvaris' Price Target to $35 From $24, Outperform Rating Kept	12-06	MT
Job losses delight investors	12-06
Morgan Stanley Adjusts Price Target on Pharvaris to $32 From $34, Maintains Overweight Rating	11-14	MT
Wedbush Lowers Pharvaris' PT to $24 From $27, Increases Share Count Assumptions Following Q3 Update, Keeps Outperform Rating Ahead of CHAPTER-1 Data	11-03	MT
Wedbush Initiates Pharvaris at Outperform With $27 Price Target, Sees Opportunity for PHVS416 in the Acute HAE Therapeutic Setting	25/09/23	MT
Wedbush Initiates Pharvaris at Outpeform With $27 Price Target	25/09/23	MT
Morgan Stanley Upgrades Pharvaris to Overweight From Equalweight, Boosts Price Target to $34 From $10	15/08/23	MT
Oppenheimer Raises Pharvaris Price Target to $26 From $24, Maintains Outperform Rating	27/06/23	MT
JMP Securities Adjusts Pharvaris' Price Target to $20 From $23, Keeps Market Outperform Rating	06/04/23	MT
SVB Securities Adjusts Pharvaris' Price Target to $18 From $20, Keeps Outperform Rating	03/02/23	MT
JMP Securities Adjusts Pharvaris' Price Target to $23 From $22, Keeps Market Outperform Rating	11/01/23	MT
JMP Securities Adjusts Price Target on Pharvaris to $22 From $18, Maintains Market Outperform Rating	09/12/22	MT
Oppenheimer Adjusts Pharvaris Price Target to $24 From $22, Maintains Outperform Rating	09/12/22	MT
SVB Securities Adjusts Price Target on Pharvaris to $20 From $25, Keeps Outperform Rating	14/09/22	MT
Oppenheimer Adjusts Pharvaris Price Target to $22 From $48, Maintains Outperform Rating	23/08/22	MT
SVB Securities Adjusts Pharvaris' Price Target to $25 From $45, Maintains Outperform Rating	23/08/22	MT
Morgan Stanley Lowers Pharvaris to Equalweight From Overweight, Price Target to $10 From $40	23/08/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Analyst Reco.

Filters